HLA-A*1101 & B2M & KRASG12R (VVVGARGVGK)

The peptide VVVGARGVGK, derived from the KRAS G12R mutation and presented by the HLA-A*11:01/β2-microglobulin (β2m) complex, is a pivotal antigenic target in antitumor immunity. This complex plays a crucial role by activating specific cytotoxic T lymphocytes (CTLs), enabling the immune system to recognize and eliminate tumor cells harboring the KRAS G12R mutation.